

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 534438474 US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 29, 2006

Signature:

(Rosemarie Puljic-Salmeron)

Docket No.: 475512000100  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Steven M. WATKINS

Application No.: 10/753,289

Confirmation No.: 1703

Filed: January 5, 2004

Art Unit: 1631

For: GENERATING, VIEWING, INTERPRETING,  
AND UTILIZING A QUANTITATIVE  
DATABASE OF METABOLITES

Examiner: R. Negin

**RESPONSE TO RESTRICTION/ELECTION OF SPECIES REQUIREMENT AND  
PRELIMINARY AMENDMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Restriction/Election of Species Requirement set forth in the non-final Office Action mailed June 29, 2006 (Paper No. 20060622), for which a response is due July 29, 2006. Filed herewith is a Petition and fee for a two month extension of time, thereby extending the deadline for response to September 29, 2006. Accordingly this response is timely filed.

Applicant hereby elects Group I (claims 2-19, as amended, and new claims 54-57), without traverse, for continued examination. In addition, Applicant elects the following five species, without traverse:

Category #1: 5,8,11-eicosatrienoic acid and 5,8,11,14,17-eicosapentaenoic acid, upon which claims 2-19 and 54-57 are readable;

Category #2: 18:2n6, upon which claims 2-7, 9-19, and 54-57 are readable;

Category #3: 5-cholesten-3b-ol, upon which claims 2-6, 8-19, and 54-57 are readable;

Category #4: cardiolipin, upon which claims 2-7, 9-19, and 54-57 are readable;  
and

Category #5: dipentadecaenoyl phosphatidylethanolamine, upon which claims 2-7, 9-10, 12-19, and 54-57 are readable.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Remarks** begin on page 8 of this paper.